Urine Immunogram
Urine Immunogram
The urine immunogram is a groundbreaking tool in oncology, offering critical insights into a patient’s immune status to assist in diagnosing, monitoring, and treating various cancers. It serves as a reliable method to track disease progression by monitoring levels of tumor-specific antigens in urine, providing an assessment of the effectiveness of cancer treatments. Furthermore, it measures the presence and activity of immune cells within a tumor microenvironment, aiding in predicting patients’ responsiveness to immunotherapy. Although, the urine immunogram in it’s research phase, it might become an essential tool in enhancing the personalized and effective treatment of cancer
Urine Immunogram And Cancer Epigenetics
One of our prominent research projects revolves around the concept of a next-generation Urine Immunogram. The primary aim of this groundbreaking research is to identify the transition of bladder cancer to its muscle-invasive phase using a non-invasive method – a urine test
The Research Methodology
Our novel approach focuses on deciphering immune cell-specific cfDNA methylation markers present in the urine. This pioneering methodology taps into the field of cancer epigenetics, focusing on modifications that control gene expression rather than altering the DNA sequence itself.
By investigating these markers, we hope to better understand the dynamic interactions between the immune system and cancer, and detect crucial changes indicative of the disease’s progression.
Alongside this, we’re also phenotyping the immune sediment found in urine for exhaustion markers. Immune cell exhaustion is a state of dysfunction that commonly occurs in the cancer microenvironment, leading to reduced immune cell response to cancer cells.
The Patients We Serve
Our study primarily focuses on patients diagnosed with early-stage urothelial non-muscle invasive disease. This pioneering research has the potential to drastically change the way we monitor these patients, providing an early warning system for disease progression.
By identifying the transition of bladder cancer to a muscle-invasive phase at an early stage, this non-invasive urine test could enable timely intervention, potentially improving patient outcomes.
Pioneering the Future
At HCRI, we’re committed to pioneering research that opens up new frontiers in cancer diagnosis and treatment. Our work on the Urine Immunogram and its potential to detect crucial changes in bladder cancer is a testament to our innovative spirit.
In our quest to unravel cancer’s mysteries, we strive to offer hope and redefine cancer care. Our work on cancer epigenetics is just one of the ways we’re pushing the boundaries of what’s possible in cancer research. Through our relentless pursuit of innovation, we aim to transform the lives of those touched by cancer, one discovery at a time.
